Xbrane publishes answers to questions received in recent days.

Following the communication regarding the delay in FDA approval for Lucamzi (Ximluci in the U.S.) and the Q3 report, Xbrane has received numerous questions. As many stakeholders have raised similar concerns, we have done our best to address these questions in the attached document.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

Xbrane publishes answers to questions received in recent days.
Q&A Q3 2025 EN